Clinical Trial Update: Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial of vincristine sulfate liposome for relapsed or refractory acute myeloid leukemia has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Vincristine sulfate liposome (vincristine sulfate liposome)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Recurrent Adult Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2019-08-01